BioStock: Sensidose’s CEO looks towards autumn after strong growth

Sensidose can greet the halfway point of 2022 with a strong cash position after its listing on Spotlight and rising sales despite a shortage of components. In addition, the company recently submitted an application for certification of the dosing apparatus MyFID under MDR, the new regulatory framework for medical devices. BioStock talked to CEO Jack Spira regarding the achievements of the first half of the year and the outlook for autumn.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/sensidoses-ceo-looks-towards-autumn-after-strong-growth/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se